Canagliflozin and cardiovascular and renal events in type 2 diabetes

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Postgraduate medicine

• Publication date

  2018-01-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/00325481.2018.1423852PMID 29297732
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial)

  2019cited by this paper
• Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?

  2017cited by this paper
• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

  2017cited by this paper
• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

  2017influential reference
• All-Cause Mortality in Patients With Diabetes Under Treatment With Dapagliflozin: A Population-Based, Open-Cohort Study in The Health Improvement Network Database

  2017cited by this paper
• Antihyperglycemic Medications and Cardiovascular Risk Reduction

  2017influential reference
• Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials

  2017cited by this paper
• Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs

  2017cited by this paper
• Clinical Perspective What Is New ?

  2017cited by this paper
• Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes.

  2017cited by this paper
• Erratum. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes Care 2017;40:813–820

  2017cited by this paper
• Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.

  2016influential reference
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2016influential reference
• Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?

  2016cited by this paper
• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

  2016influential reference
• Empagliflozin reduces cardiovascular events and mortality in type 2 diabetes

  2016cited by this paper
• Association of Cardiometabolic Multimorbidity With Mortality.

  2015cited by this paper
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2015cited by this paper
• Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

  2011cited by this paper
• Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

  2010cited by this paper
• Age and the burden of death attributable to diabetes in the United States.

  2002cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper

• The urinary albumin‐to‐creatinine ratio can direct personalized prevention and treatment for cardiovascular and chronic kidney disease

  2026cites this paper
• Optimal Medical Therapy Targeting Metabolic Status for Secondary Prevention in Patients Undergoing Percutaneous Coronary Intervention

  2026cites this paper
• Role of Sodium-Glucose Transport Protein-2 Inhibitors in Renal Protection: A Narrative Review from the Cardiovascular-Kidney-Metabolic Interconnection

  2026influential citation
• Old Drug, New Opportunity: Drug Repurposing in Cardiovascular Diseases

  2026cites this paper
• Prevalence and associated factors of diabetic kidney disease among rural patients with type 2 diabetes mellitus in Guangxi, China: a cross-sectional study

  2026cites this paper
• Sex differences in trial representation and the cardiovascular effectiveness of newer glucose‐lowering agents in patients with and without type 2 diabetes: A systematic review and meta‐analysis of cardiovascular outcome trials

  2026cites this paper
• A Systematic Review of Pharmacodynamics and Cardio-Renal Outcomes of SGLT-2 and DPP-4 Inhibition in Type 2 Diabetes Mellitus

  2026cites this paper
• The Potential Role of SGLT2 Inhibitors in the Treatment of Depression: Mechanisms and Clinical Prospects

  2026cites this paper
• Association of SGLT2 inhibitors use with a lower risk of biliary diseases in patients with type 2 diabetes mellitus: a retrospective cohort study

  2026cites this paper
• Who is missing from SGLT-2 inhibitor trials? implications for drug safety and seneralizability: a systematic review and meta-analysis.

  2026cites this paper
• Rol de los ISGLT2 en la protección renal más allá de la diabetes

  2026cites this paper
• In Vitro Evaluation of Bilayer Tablets Comprising Immediate Release Canagliflozin and Sustained Release Vildagliptin

  2026cites this paper
• Dapagliflozin targets RORγt to improve myocardial ischemia-reperfusion injury-induced heart failure by regulating the CD4+ T cell/Th17 cell axis within cardiac tissue.

  2026cites this paper
• Cardiovascular and renal outcomes of sodium–glucose cotransporter-2 versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes post-PCI: a meta-analysis of 14,511 patients

  2026cites this paper
• Comparative effects of second-line oral antidiabetic medications on atrial fibrillation risk in patients with type 2 diabetes: a nationwide retrospective cohort study

  2026cites this paper
• Mechanisms of SGLT inhibitor action and physiological mediators: systematic review and protocol for the MOSAIC collaborative meta-analysis

  2026cites this paper
• Timing-dependent anti-inflammatory effects of empagliflozin in monocyte-derived macrophages from post-myocardial infarct patients with type 2 diabetes

  2026cites this paper
• The effect of sodium‐glucose cotransporter 2 inhibitors on HbA1c variability and cardiovascular and renal adverse outcome in patients with T2DM

  2025cites this paper
• Heterogeneity of Treatment Effects of Glucose-lowering Drug Classes for Type 2 Diabetes: LEGEND-T2DM Network Real-World Evidence

  2025cites this paper
• Update on the pathophysiology and treatment of diabetic kidney disease: a narrative review

  2025cites this paper
• Impact of SGLT2-inhibitors on acute kidney injury in diabetic patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI)

  2025cites this paper
• Comparative Safety of Second-Line Antihyperglycemic Agents in Older Adults with Type 2 Diabetes: A Multinational Real-World Evidence From LEGEND-T2DM

  2025cites this paper
• Impact of baseline left ventricular ejection fraction and body mass index on the effect of 24-week Ipragliflozin treatment on left ventricular diastolic function in patients with type 2 diabetes and chronic kidney disease: insights from the PROCEED trial

  2025cites this paper
• Canagliflozin Delays Aortic Valve Calcification by Enhancing the AMPK/Nrf2/HO‐1 Antioxidant Signaling Pathway in Valvular Interstitial Cells

  2025cites this paper
• The effects of SGLT2i on cardiac metabolism in patients with HFpEF: Fact or fiction?

  2025cites this paper
• Long‐term outcomes following alternative second‐line oral glucose‐lowering treatments: Results from the real‐world progression in type 2 diabetes mellitus United Kingdom (RAPIDS‐UK) model

  2025cites this paper
• Clinical Decision-Making for Patients with Chronic Limb-Threatening Ischemia.

  2025cites this paper
• Comparative effectiveness of alternative second-line oral glucose-lowering therapies for type 2 diabetes: a precision medicine approach applied to routine data

  2025cites this paper
• Cardiometabolic Dysregulation and Heart Failure

  2025cites this paper
• The use of SGLT2 inhibitors in people with diabetes‐related foot disease: A Delphi‐based consensus study

  2025cites this paper
• Comparison of New‐Onset Peripheral Artery Disease in Patients With Type 2 Diabetes Exposed to Sodium–Glucose Cotransporter‐2 Inhibitors, Dipeptidyl Peptidase‐4 Inhibitors, or Glucagon‐Like Peptide‐1 Agonists: A Population‐Based Cohort Study

  2025cites this paper
• Predictors of diabetic ketoacidosis in patients with insulin‐deficient diabetes phenotype initiating SGLT2 inhibitors

  2025cites this paper
• Cardiorenal protection with dapagliflozin in patients with type 2 diabetes mellitus and chronic coronary syndrome undergoing percutaneous coronary intervention: a registry cross-sectional study

  2025cites this paper
• New Therapies for the Management of Chronic Kidney Disease

  2025cites this paper
• Association between sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis of randomized active-controlled trials

  2025cites this paper
• Use of adjunctive glycaemic agents with vascular protective properties in individuals with type 1 diabetes: Potential benefits and risks

  2025cites this paper
• Effect of administration and withdrawal of the sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, on renal protection in individuals with type 2 diabetes mellitus and diabetic nephropathy: A multicenter, single‐arm study (RESTORE‐nephropathy study)

  2025cites this paper
• Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Nervous System Disorders: A Systematic Review and Meta-Analysis

  2025cites this paper
• Efficacy and Safety of Early Initiation of Sodium–Glucose Co-transporter-2 Inhibitors Following Acute Myocardial Infarction: A Systematic Review and Meta-analysis

  2025cites this paper
• Effects of SGLT2 Inhibitors on Cardiovascular and Lower Limb Events in Patients with Type 2 Diabetes: A Nationwide Population-Based Study

  2025influential citation
• Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: insights from the CREDENCE trial

  2025cites this paper
• Management of Diabetes in Patients with Chronic Kidney Disease

  2025cites this paper
• Advancements in SGLT2 inhibitors: pharmacokinetics, pharmacodynamics, and clinical efficacy with a focus on pharmacogenomics

  2025cites this paper
• Mitochondrial Quality Control Systems in Septic AKI: Molecular Mechanisms and Therapeutic Implications

  2025cites this paper
• Benefits of Sodium-Glucose Cotransporter-2 Inhibitors with Renin-Angiotensin System Blockers in Type-2 Diabetes: A Cohort Analysis

  2025cites this paper
• Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18‐month follow‐up of a randomized clinical trial

  2025cites this paper
• Efficacy and safety of empagliflozin in patients over 65 with type 2 diabetes mellitus complicating cardiorenal syndromes type II and IV

  2025cites this paper
• Adipokines and Adipose Tissue: The Role and Use of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors in Patients with Diabetes or Heart Failure

  2025cites this paper
• Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes

  2025cites this paper
• SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application

  2025cites this paper
• Effects of SGLT2 inhibitors on ion channels in heart failure: focus on the endothelium

  2025cites this paper
• Effect of dapagliflozin on the no-reflow phenomenon in patients with acute myocardial infarction and type II diabetes mellitus

  2025cites this paper
• A validated multivariable machine learning model to predict cardio-kidney risk in diabetic kidney disease

  2025cites this paper
• Risk of Hearing Loss in Patients Treated with Exendin-4 Derivatives: A Network Meta-Analysis of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors

  2025cites this paper
• The Role of Diabetes and SGLT2 Inhibitors in Cerebrovascular Diseases

  2025cites this paper
• Impact of sodium–glucose transport protein-2 (SGLT2) inhibitors on the inflammasome pathway in acute myocardial infarction in type 2 diabetes mellitus: a comprehensive review

  2025influential citation
• Dapagliflozin, Empagliflozin ve Eksenatid Kullanan Tip 2 Diyabetli Hastalarda Kardiyovasküler Olay Oranlarının Retrospektif Olarak Değerlendirilmesi

  2025cites this paper
• Suboptimal physician adherence to evidence‐based guidelines for managing cardiorenal comorbidities in diabetes care: A retrospective single‐center study in Taiwan

  2025cites this paper
• Advancing antihypertensive drug development

  2025cites this paper
• Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome

  2025cites this paper
• The combined impact of chronic kidney disease and ulcer severity on incident cardiovascular events in patients with diabetes‐related foot ulceration

  2025cites this paper
• Effects of sodium-glucose cotransporter 2 inhibitors on cardiomyopathy: a meta-analysis

  2025influential citation
• Metformin and risk factors for chronic kidney disease in a European population based on Mendelian randomization

  2025cites this paper
• Use of evidence-based cardiovascular preventive therapies in type 2 diabetes patients with established or high risk of atherosclerotic cardiovascular disease in China: A retrospective cohort study

  2025cites this paper
• Effect of SGLT2i on kidney outcomes of individuals with type 2 diabetes according to body mass index: nationwide cohort study

  2025cites this paper
• Water and electrolyte abnormalities in novel pharmacological agents for kidney disease and cancer

  2025cites this paper
• Revisiting the association between sodium-glucose cotransporter-2 inhibitors and the risk of neoplasm in patients with type 2 diabetes: new insights from an updated systematic review and meta-analysis of randomized controlled trials

  2025cites this paper
• Age-dependent effects of SGLT2 inhibitors on stroke risk in geriatric patients with diabetes and atrial fibrillation

  2025cites this paper
• Empagliflozin Reduces High Glucose-Induced Cardiomyopathy in hiPSC-Derived Cardiomyocytes

  2025cites this paper
• Use of Potentially Nephrotoxic Drugs in Type 2 Diabetes Patients on SGLT2i: A Trajectories Analysis

  2025cites this paper
• Risk-directed management of chronic kidney disease

  2025cites this paper
• Ranibizumab with luseogliflozin in type 2 diabetes with diabetic macular oedema: A randomised clinical trial

  2025cites this paper
• Update on the Efficacy and Safety of Sodium–Glucose Co-Transporter 2 Inhibitors in Patients with Chronic Diseases: A Systematic Review and Meta-Analysis

  2025cites this paper
• Dapagliflozin inhibits ferroptosis to improve chronic heart failure by regulating Nrf2/HO-1/GPX4 signaling pathway

  2025cites this paper
• Dapagliflozin alleviated seizures and cognition impairment in pilocarpine induced status epilepticus via suppressing microglia-mediated neuroinflammation and oxidative stress.

  2025cites this paper
• Left Ventricular Global Longitudinal Strain: an Early Marker of Diabetic Cardiomyopathy

  2025cites this paper
• Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter-2 inhibitors in atherosclerotic cardiovascular disease phenotypes: a systematic review and meta-analysis

  2025cites this paper
• Management kardiovaskulärer Erkrankungen bei Patienten mit Diabetes

  2025cites this paper
• Impact of sodium‒glucose cotransporter‐2 inhibitors in patients with recent versus previous myocardial infarction: a systematic review and meta-analysis

  2025cites this paper
• Anti-inflammatory Therapies for Ischemic Heart Disease

  2025cites this paper
• Role of anti-diabetic medications in the management of MASLD

  2025cites this paper
• PEPPSI-type N-heterocyclic carbene palladium(II) complexes as catalysts in the direct C5 arylation of furan and thiophene

  2025cites this paper
• The impact of metformin on kidney disease progression and mortality in diabetic patients using SGLT2 inhibitors: a real-world cohort study

  2025cites this paper
• Effect of sodium-glucose Co-transporter 2 inhibitors on coronary microcirculation

  2025cites this paper
• Analysis of specialist doctors’ behavior towards SGLT2 inhibitors prescription in Indonesia: A qualitative study

  2025cites this paper
• Real-World Comparisons Between Glucagon-Like Peptide-1 Receptor Agonists and Other Glucose-Lowering Agents in Type 2 Diabetes: Retrospective Analyses of Cardiovascular and Economic Outcomes in England

  2025cites this paper
• Effects of oral antidiabetic agents on the renin–angiotensin–aldosterone system

  2025cites this paper
• SGLT2 inhibitor use and renal outcomes in low-risk population with diabetes mellitus and normal or low body mass index

  2025cites this paper
• Mitochondria for Cardiovascular Therapy: A Deep Dive into Drug Targets and Therapeutic Approaches

  2025cites this paper
• The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis

  2025cites this paper
• Unveiling the bladder’s early response to acute glucosuria: first evidence from an animal study

  2025cites this paper
• Direct Cardiac Mechanisms of the Sodium Glucose Co-Transporter 2 Inhibitor Class

  2025cites this paper
• Diabetes Mellitus and Associated Vascular Disease: Pathogenesis, Complications, and Evolving Treatments

  2025cites this paper
• Effects of sodium–glucose cotransporter 2 inhibitors in patients with cancer and diabetes mellitus: a systematic review and meta-analysis

  2025influential citation
• Mechanistic insights and emerging therapeutic strategies targeting endothelial dysfunction in cardiovascular diseases

  2025influential citation
• Canagliflozin-driven cellular re-differentiation and migration inhibition in vascular smooth muscle cells via PTEN upregulation

  2025cites this paper
• Risk and management of cardiac disease in kidney and liver transplant recipients

  2025cites this paper
• Research priorities for peripheral artery disease: A statement from the Society for Vascular Medicine

  2025cites this paper
• CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes

  2025cites this paper
• The effects of type 1 and type 2 diabetes mellitus on bone health in chronic kidney disease

  2025influential citation